Impedimed (ASX:IPD) 3-Year Revenue Growth Rate

: -15.70% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

Impedimed's Revenue per Share for the six months ended in Dec. 2023 was A$0.00.

During the past 12 months, Impedimed's average Revenue per Share Growth Rate was -50.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -15.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -14.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was -10.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Impedimed was 6.70% per year. The lowest was -22.40% per year. And the median was -14.15% per year.

Competitive Comparison

For the Medical Devices subindustry, Impedimed's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Impedimed 3-Year Revenue Growth Rate Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Impedimed's 3-Year Revenue Growth Rate falls into.

Impedimed 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Impedimed (ASX:IPD) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Impedimed 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Impedimed's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Impedimed (ASX:IPD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Impedimed Ltd (ASX:IPD) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

IPDQF:USA

Address

50 Parker Court, Unit 1, Pinkenba, QLD, AUS, 4008

Website

https://www.impedimed.com

Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates most of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The Company recognizes revenue from stand alone sale of Legacy Devices and Consumables, Sale of SOZO Device and Software Subscription Services.

Impedimed (ASX:IPD) Headlines

No Headlines